CE
Cell Bio Human Tech Co., Ltd
318160 | KO
Overview
Corporate Details
- ISIN(s):
- KR7318160009
- LEI:
- Country:
- South Korea
- Address:
- 경기도 안양시 동안구 시민대로 401 대륭테크노타운15차 제2001호,제2101호, 안양시
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-19 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
|
Korean | 31.8 KB | ||
| 2025-09-19 00:00 |
Capital/Financing Update
주요사항보고서(교환사채권발행결정)
|
Korean | 53.0 KB | ||
| 2025-08-28 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
|
Korean | 28.2 KB | ||
| 2025-08-28 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
|
Korean | 28.2 KB | ||
| 2025-08-28 00:00 |
Transaction in Own Shares
신탁계약해지결과보고서
|
Korean | 20.6 KB | ||
| 2025-08-28 00:00 |
Transaction in Own Shares
신탁계약해지결과보고서
|
Korean | 22.3 KB | ||
| 2025-08-28 00:00 |
Transaction in Own Shares
[기재정정]주요사항보고서(자기주식취득신탁계약해지결정)
|
Korean | 31.1 KB | ||
| 2025-08-28 00:00 |
Interim / Quarterly Report
[기재정정]반기보고서 (2025.06)
|
Korean | 1.2 MB | ||
| 2025-08-18 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.3 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.2 MB | ||
| 2025-06-02 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 7.0 KB | ||
| 2025-05-27 00:00 |
Major Shareholding Notification
신탁계약에의한취득상황보고서
|
Korean | 52.6 KB | ||
| 2025-05-27 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.3 KB | ||
| 2025-05-14 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.1 MB | ||
| 2025-04-02 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.4 KB |
Automate Your Workflow. Get a real-time feed of all Cell Bio Human Tech Co., Ltd filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Cell Bio Human Tech Co., Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cell Bio Human Tech Co., Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing nsPFA bioelectric tech for precise, non-thermal tissue ablation in cardiology.
United States of America
PLSE
United States of America
PLSE
Clinical-stage biotech developing biologic therapies for autoimmune and inflammatory diseases.
United States of America
QTTB
United States of America
QTTB
Global defence & security firm providing tech solutions, test & evaluation for government clients.
United Kingdom
QQ
United Kingdom
QQ
A clinical-stage company developing innovative treatments for rare cancers in adults and children.
United States of America
QLGN
United States of America
QLGN
Offers an ultra-sensitive immunoassay platform for biomarker analysis in research and diagnostics.
United States of America
QTRX
United States of America
QTRX
United Kingdom
QUBE
R&D firm using AI and quantum computing to create efficient technologies for Bitcoin mining.
United Kingdom
QBT
United Kingdom
QBT
Develops biobetters by enhancing approved drugs with a patented drug delivery platform.
Sweden
QUIA
Sweden
QUIA
Biopharma developing novel drugs for cancer, inflammation, and infectious diseases.
South Korea
115180
South Korea
115180
Developing first-in-class radiopharmaceuticals for the diagnosis and treatment of cancer.
United States of America
RADX
United States of America
RADX